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Pegylated amphotericin B (AmB) liposomes (PEG-AmB-LIP) were compared with laboratory-prepared
nonpegylated AmB liposomes (AmB-LIP), a formulation with a lipid composition the same as that in AmBi-
some, as well as with industrially prepared AmBisome regarding their in vitro antifungal activities, toxicities,
blood residence times, and therapeutic efficacies. Killing of Candida albicans (>99.9%) during short-term (6-h)
incubation was observed at 0.2 mg of AmB per liter for AmB desoxycholate, 0.4 mg of AmB per liter for
PEG-AmB-LIP, 0.8 mg of AmB per liter for AmB-LIP, and 12.8 mg of AmB per liter for AmBisome. The
maximum tolerated doses of PEG-AmB-LIP, AmB-LIP, and AmBisome were 15, 19, and >31 mg of AmB per
kg of body weight, respectively. In contrast to AmB-LIP, the blood residence time of PEG-AmB-LIP was
prolonged and dose independent. In a model of systemic candidiasis in leukopenic mice at a dose of 5 mg of
AmB per kg, PEG-AmB-LIP was completely effective and AmB-LIP was partially effective, whereas AmBisome
was not effective. AmB-LIP at 11 mg of AmB per kg was partially effective. AmBisome at 29 mg of AmB per kg
was completely effective. In conclusion, the therapeutic efficacies of AmB liposomes can be improved by
preparing AmB liposomes in which a substantial reduction in toxicity is achieved while antifungal activity is
retained. In addition, therapeutic efficacy is favored by a prolonged residence time of AmB liposomes in blood.
There has been a steady increase in the incidence of invasive
fungal infections in immunocompromised patients. These in-
fections are among the most important causes of morbidity and
mortality among patients with cancer and among other se-
verely immunocompromised hosts. Because the overall prog-
nosis for patients with invasive fungal infections remains poor,
there is a critical need to improve the methods for treating
these infections.
Parenteral administration of amphotericin B (AmB) re-
mains the therapy of choice for most invasive fungal infections.
AmB is administered as AmB desoxycholate (AmB-DOC;
Fungizone), but its clinical use is limited by toxic side effects
(15, 23). A promising approach to the treatment of deep sys-
temic fungal infections is the use of AmB incorporated into
liposomes or other lipid carriers (12, 16, 27). With respect to
the industrially produced preparations AmBisome, AmB lipid
complex, and Amphocil, it is evident that these have quite
different structural and pharmacokinetic characteristics (20,
27). The relatively large structures of the AmB lipid complex as
well as the small discoidal particles of Amphocil are rapidly
taken up by the mononuclear phagocyte system, whereas small
liposomes such as those used in the AmBisome formulation
remain in the circulation for relatively prolonged periods. Un-
til now it has not been known whether a long blood residence
time is of importance for the improved efficacies of AmB
liposomes.
The ability to achieve a significantly longer blood residence
time of liposomes opens new ways to achieving improved de-
livery of antimicrobial agents to infected tissues including in-
fections in non-mononuclear phagocyte system tissues (8).
Recently, many reports have shown that hydrophilic phos-
phatidylethanolamine derivatives of monomethoxypolyethyl-
eneglycols (PEG-PE) attached to the liposomes can effectively
prolong their blood circulation times without the limitations of
lipid dose, small particle size, or rigid lipid composition (2–5, 8,
9, 21, 22, 25, 32, 33). Such liposomes have been named steri-
cally stabilized liposomes. The distinctive properties of steri-
cally stabilized liposomes make them excellent candidates for
many therapeutic applications.
In our laboratory it was recently shown (30) that long-circu-
lating AmB-containing liposomes can be prepared by incorpo-
ration of polyethylene glycol 1900 (PEG)-derivatized dis-
tearoylphosphatidylethanolamine (DSPE), which is referred to
as PEG-DSPE. In the present study the effects of incorpora-
tion of PEG-DSPE in AmB liposomes on in vitro antifungal
activity, toxicity, and efficacy in leukopenic mice with systemic
candidiasis are reported. The pegylated AmB liposome (PEG-
AmB-LIP) formulation was compared with laboratory-pre-
pared nonpegylated AmB liposomes (AmB-LIP), a formula-
tion with a lipid composition the same as that in AmBisome, as
well as with industrially prepared AmBisome.
MATERIALS AND METHODS
Materials. Antibiotic medium 3 was from Difco Laboratories (Detroit, Mich.).
Sabouraud dextrose agar was from Oxoid (Basingstoke, England). AmB and
AmB-DOC (Fungizone for intravenous infusion) were kindly provided by Bristol
Myers-Squibb, Woerden, The Netherlands. AmB-DOC was reconstituted with
distilled water to give a standard solution of 5 g of AmB per liter AmBisome,
consisting of hydrogenated soybean phosphatidylcholine (HSPC), cholesterol
(Chol), distearoylphosphatidylglycerol (DSPG), and AmB in a molar ratio of
2:1:0.8:0.4, and lipid powder, consisting of HSPC, Chol, DSPG, and AmB in a
molar ratio of 2:1:0.8:0.4 in which AmB is complexed to DSPG, were both kindly
provided by Vestar, Inc. (San Dimas, Calif.). HSPC, Chol, monomethoxypoly-
ethyleneglycol 1900 succinimidyl succinate (activated PEG), and DSPE were all
kindly provided by Vestar Inc. Dimethyl sulfoxide (DMSO) was from Janssen
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Chimica (Tilburg, The Netherlands). Deferoxamine mesylate (DF) was from
Ciba-Geigy (Basel, Switzerland). 67Ga-citrate was from Nordian (Montreal, Can-
ada), and 111In-chloride was from Frosst (Quebec, Canada). Hydroxyquinoline
sulfate (oxine) and cyclophosphamide were from Sigma (St. Louis, Mo.). PEG-
DSPE was synthesized as described by Blume and Cevc (9).
Candida strain. Candida albicans ATCC 44858 was used in all of the experi-
ments and was stored at 2808C in Todd-Hewitt broth (Difco) containing 10%
(vol/vol) glycerol.
Animals. Specific-pathogen-free female BALB/c mice (ages, 12 to 20 weeks)
were obtained from Iffa Credo (L’Arbresle, France).
Liposome preparation. Liposome preparations consisted of PEG-DSPE–
HSPC–Chol–AmB (PEG-AmB-LIP) in a molar ratio of 0.21:1.79:1:0.32, PEG-
DSPE–HSPC–Chol (PEG-PLACEBO-LIP) in a molar ratio of 0.21:1.79:1,
HSPC-Chol-DSPG-AmB (AmB-LIP) in a molar ratio of 2:1:0.8:0.4, and HSPC-
Chol-DSPG (PLACEBO-LIP) in a molar ratio of 2:1:0.8. AmB is very poorly
soluble in chloroform-methanol (1:1; vol/vol), and therefore, as a first step in the
preparation of AmB-containing liposomes, AmB was complexed to either PEG-
DSPE (PEG-AmB-LIP) or DSPG (AmB-LIP). For PEG-AmB-LIP, AmB was
complexed to PEG-DSPE by adding small volumes (20 to 50 ml) of 1 N HCl to
a suspension of AmB and PEG-DSPE in 2 ml of chloroform-methanol (1:1;
vol/vol); this was followed by heating at 658C and vortex mixing until the solution
cleared. Small volumes (10 to 15 ml) of 1 N NaOH were added; this was followed
by the addition of HSPC and Chol. When precipitation of AmB was observed,
small volumes of 1 N HCl were again added until the solution cleared. This lipid
mixture was evaporated to dryness in a round-bottom flask at 658C. For PEG-
PLACEBO-LIP, AmB-LIP, and PLACEBO-LIP, a chloroform-methanol (1:1;
vol/vol) solution of lipid mixture or lipid powder was evaporated to dryness in a
round-bottom flask at 658C. The lipid film was hydrated by vortex mixing in a
buffer solution containing 10 mM sodium-succinate and 10% (wt/vol) sucrose
(pH 5.5) at 658C. For biodistribution experiments, 5 mM DF was added to this
buffer. Liposomes were sonicated, resulting in an average particle size of 100 nm
(range, 95 to 105 nm), as measured by dynamic light scattering (4700 system;
Malvern, Malvern, United Kingdom). Biodistribution of intact liposomes was
performed with liposomes radiolabeled with 67Ga-DF as described by Woodle
(31). The labeling resulted in the formation of a 67Ga-DF complex in the
aqueous interiors of the liposomes. As shown by Gabizon et al. (14), this complex
is appropriate for in vivo tracing of intact liposomes because of the advantages
of minimal translocation of radioactive label to plasma proteins and the rapid
renal clearance rate when the label is released from the liposomes. Liposomes
were separated from nonentrapped AmB, DF, or radiolabel by gel filtration on
a Sephadex G-50 column (Pharmacia, Uppsala, Sweden) and were concentrated
by using 300-kDa Microsep filters (Filtron, Breda, The Netherlands). Phospho-
lipid concentration was determined by a phosphate assay (6). The AmB concen-
tration was determined spectrophotometrically at 405 nm after destruction of the
liposomes in DMSO-methanol (1:1; vol/vol).
AmBisome, consisting of HSPC, Chol, DSPG, and AmB in a molar ratio of
2:1:0.8:0.4, was provided as a lyophilized preparation. The powder was reconsti-
tuted according to the manufacturer’s instructions with distilled water at 658C to
give a liposomal suspension containing 4 g of AmB per liter and 35 g of lipid per
liter, with an average liposome particle size of 90 nm (range, 88 to 92 nm).
In vitro antifungal activities of AmB-DOC, PEG-AmB-LIP, AmB-LIP, and
AmBisome. The in vitro activities of AmB-DOC, PEG-AmB-LIP, AmB-LIP, and
AmBisome in terms of effective killing (.99.9%) of C. albicans at an inoculum
of 1.3 3 107 CFU/liter during 6 h of incubation were determined as described
previously (29). Briefly, a logarithmic-growth-phase culture of C. albicans was
prepared. C. albicans was exposed during 6 h of incubation to twofold increasing
concentrations of each agent in antibiotic medium 3, ranging from 0.05 to 25.6
mg of AmB per liter. During incubation the numbers of viable C. albicans were
determined at 2-h intervals by making plate counts of 10-fold serial dilutions of
the washed specimen on Sabouraud dextrose agar.
Determination of MTD. The toxicities of PEG-AmB-LIP, AmB-LIP, and Am-
Bisome were measured in uninfected mice. Mice (six per group) were treated
intravenously with a single dose. AmB dosages ranged from 1 to 31 mg/kg of
body weight in steps of 2 mg/kg. Acute mortality was assessed directly following
injection of the preparation. Blood urea nitrogen and serum creatinine levels as
parameters for renal toxicity and aspartate aminotransferase and alanine ami-
notransferase levels as parameters for liver toxicity were determined by estab-
lished methods in serum samples from mice sacrificed at 48 h after the termi-
nation of treatment. The maximum tolerated dose (MTD) was defined as the
maximum dose that did not result in death or more than a threefold increase in
the indices for renal and liver function compared with those for untreated mice.
Blood residence time of PEG-AmB-LIP versus that of AmB-LIP at various
dosages in uninfected mice. 67Ga-DF-labeled liposomes were administered in-
travenously at 0.5 or 5 mg of AmB per kg (equivalent to 4.7 or 47 mmol of
liposomal lipid per kg, respectively) as a single dose in uninfected mice. In two
separate experiments, the levels of 67Ga-DF as well as those of AmB in blood
were determined at various time points during 24 h after administration; three
mice were used for each time point in each experiment. Blood was collected in
heparinized tubes. The 67Ga-DF levels in blood samples (200 ml) as well as those
in the doses of the injected liposomes were counted in a gamma counter (Minaxy
5530; Packard Instruments, Downers Grove, Ill.). Additionally, at 5 mg/kg, AmB
concentrations were determined in these blood samples. For determination of
AmB concentrations in blood, samples from three mice were pooled and stored
at 2808C until just before high-performance liquid chromatography (HPLC)
analysis, which was performed as described before (29). In a separate experiment
with 111In-labeled syngeneic erythrocytes (18), the total blood volume in the mice
was determined.
Efficacies of PEG-AmB-LIP, AmB-LIP, and AmBisome in leukopenic mice
infected with C. albicans. Leukopenia was induced by intraperitoneal adminis-
tration of cyclophosphamide at 100 mg/kg 4 days before C. albicans inoculation.
This was followed by the administration of an additional dose of 75 mg/kg on the
day of inoculation and the same dose at 3-day intervals thereafter. This treatment
resulted in persistent granulocytopenia (,0.1 3 109/liter) from the time of C.
albicans inoculation to the termination of the study. Leukopenic mice were
infected by inoculation of 33 104 CFU C. albicans into the tail vein. PEG-AmB-
LIP, AmB-LIP, AmBisome, and placebo were each administered intravenously
as a single dose at 20 h after C. albicans inoculation at doses corresponding to
their MTDs. AmB-LIP and AmBisome were also administered at a dose which
was equivalent to the MTD of PEG-AmB-LIP. Just before treatment and at 48
h as well as 6 days after treatment, the surviving mice were sacrificed. The
kidneys, liver, spleen, and lungs were removed and processed for the determi-
nation of viable counts as described previously (29). The following criteria were
used to assess the efficacy of treatment: survival of mice up to 6 days after
treatment, a statistically significant reduction in the numbers of CFU of C.
albicans in the kidneys at 48 h after treatment compared with the numbers at the
time of treatment, and prevention of a significant increase in the numbers of
CFU of C. albicans in the kidneys at 6 days after treatment compared with the
numbers at 48 h after treatment (equating to a relapse of infection).
Statistical analysis. Results were expressed as the geometric means 6 stan-
dard deviations. Differences in the numbers of CFU of C. albicans between the
various treatment groups were analyzed by the Mann-Whitney test.
RESULTS
In vitro antifungal activities of AmB-DOC, PEG-AmB-LIP,
AmB-LIP, and AmBisome. For AmB-DOC, PEG-AmB-LIP,
AmB-LIP, and AmBisome the minimal AmB concentrations
required to kill .99.9% of the initial C. albicans inoculum
within 6 h of incubation were determined. With AmB-DOC,
PEG-AmB-LIP, and AmB-LIP, effective killing was obtained
with 0.2, 0.4, and 0.8 mg of AmB per liter, respectively. With
AmBisome, on the other hand, a concentration of 12.8 mg of
AmB per liter was required to produce the same fungicidal
activity.
MTDs of PEG-AmB-LIP, AmB-LIP, and AmBisome in un-
infected mice. The MTDs of PEG-AmB-LIP, AmB-LIP, and
AmBisome are presented in Table 1. With PEG-AmB-LIP the
MTD with no death after treatment was 15 mg/kg. At this dose
renal or liver toxicity was not yet observed. For AmB-LIP (a
formulation with a lipid composition the same as that in Am-
Bisome), death during treatment was shown at doses greater
than 19 mg/kg. At this dose no renal or liver toxicity was seen.
With AmBisome no toxicity was observed in terms of death or
impairments in renal or liver function up to a dose of 31 mg/kg.
Blood residence time of PEG-AmB-LIP versus that of AmB-
LIP at various doses in uninfected mice. The levels of 67Ga-DF
in blood following administration of radiolabeled PEG-AmB-
TABLE 1. MTDs of PEG-AmB-LIP, AmB-LIP, and AmBisome in
uninfected micea
Parameter of toxicity
MTD (mg of AmB/kg)b
PEG-AmB-LIP AmB-LIP AmBisome
Death after treatment 15 19 .31
Impaired renal function .15 .19 .31
Impaired liver function .15 .19 .31
aMice were treated intravenously with a single dose. AmB dosages ranged
from 1 to 31 mg/kg in steps of 2 mg/kg.
b Toxicity was determined in terms of death after treatment or more than
threefold increase in the indices for renal function (blood urea nitrogen and
serum creatinine) and liver function (aspartate aminotransferase and alanine
aminotransferase) compared with those for placebo-treated mice determined 48
h after the termination of treatment.
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LIP and AmB-LIP at doses of 0.5 mg of AmB per kg (4.7 mmol
of lipid per kg) and 5 mg of AmB per kg (47 mmol of lipid per
kg) are given in Fig. 1. 67Ga-DF was used as a marker for intact
liposomes. With PEG-AmB-LIP independent of dose a pro-
longed blood residence time of intact liposomes was observed,
with 20% of the injected dose of liposomes still circulating at
24 h after administration. For AmB-LIP it was shown that
within 5 min after administration the levels of intact liposomes
dropped to 26 and 35% of the injected dose of liposomes at
doses of 0.5 and 5 mg of AmB per kg, respectively. After this
initial drop only at the highest dose of 5 mg of AmB per kg a
prolonged blood residence time was observed, with 6% of the
injected dose circulating 12 h after administration. At the
lower dose of 0.5 mg of AmB per kg, the levels of liposomes in
blood declined to 6% of injected dose within 4 h after admin-
istration.
The levels of both 67Ga-DF and AmB in blood following
administration of radiolabeled PEG-AmB-LIP and AmB-LIP
at 5 mg of AmB per kg were determined. For both types of
liposomes, the levels of AmB declined more rapidly than the
levels of intact liposomes during circulation (data not shown).
Efficacies of PEG-AmB-LIP, AmB-LIP, and AmBisome in
leukopenic mice infected with C. albicans. In leukopenic mice
infected with C. albicans the infection is disseminated to the
kidney, liver, spleen, and lung, and untreated mice die between
24 h and 8 days after C. albicans inoculation. In these infected
mice, the MTDs of PEG-AmB-LIP, AmB-LIP, and AmBisome
in terms of acute death were 5, 11, and 29 mg of AmB per kg,
respectively. The effect of treatment on the survival of the
animals and the growth of C. albicans in the kidney is pre-
sented in Table 2. An increase in the numbers of CFU of C.
albicans was observed after placebo treatment, resulting in the
deaths of the animals. Because the placebo-treated animals
died, the numbers of C. albicans organisms in the kidneys of
these mice could not be compared with those in the kidneys of
AmB-treated mice. Treatment with PEG-AmB-LIP at the
MTD (5 mg of AmB per kg) was completely effective: 100%
survival of mice was observed, as was a significant reduction in
the numbers of C. albicans organisms in the liver (P # 0.01),
spleen (P# 0.001), and lung (P# 0.025) (data not shown). The
numbers of C. albicans organisms in the kidney were signifi-
cantly reduced at 48 h after treatment (P# 0.001), and relapse
of infection was prevented; the numbers of C. albicans organ-
isms were significantly reduced even further at 6 days after
treatment (P # 0.01). Treatment with AmB-LIP at an equiv-
alent dose (5 mg of AmB per kg) was partially effective: sur-
vival of all animals was observed, and there was also a signif-
FIG. 1. Levels of 67Ga-DF in blood after administration of radiolabeled
PEG-AmB-LIP and AmB-LIP to uninfected mice at various doses. A single dose
of 0.5 mg of AmB per kg (4.7 mmol of liposomal lipid per kg) or 5 mg of AmB
per kg (47 mmol of liposomal lipid per kg) was administered intravenously. Data
are expressed as the mean 6 standard deviation percentage of the injected dose
of 67Ga-DF in two separate experiments, with three mice in each experiment (n
5 6). The lack of error bars indicates that the range is smaller than the datum
points.
TABLE 2. Effect of treatment on survival of mice and growth of C. albicans in the kidneys of leukopenic micea
Treatmentb Dose(mg/kg)
Log10 CFU/kidney
at time of treatmentb,c
48 h after treatmentd 6 days after treatmentd
% Survival Log10 CFU/kidneyin surviving micec % Survival
Log10 CFU/kidney
in surviving micec
No. of mice with
sterile kidney/no.
of surviving mice
None 4.16 6 0.23
PEG-AmB-LIP 5 100 3.05 6 0.76e 100 1.99 6 0.42f 0/10
AmB-LIP 5 100 4.48 6 0.83 100 4.04 6 0.91 0/10
AmB-LIP 11 100 4.27 6 0.20 100 2.54 6 0.50f 0/10
AmBisome 5 70 5.26 6 0.57 40 3.92 6 0.51 0/4
AmBisome 29 100 2.60 6 0.32e 100 1.01 6 1.72f 2/10
PEG-PLACEBO-LIP 40 6.38 6 0.22 30 6.12 6 0.39 0/3
PLACEBO-LIP 50 6.56 6 0.21 10 7.39 0/1
a Leukopenic mice were inoculated intravenously at zero time with 3 3 104 CFU of C. albicans.
b PEG-AmB-LIP, AmB-LIP, AmBisome, PEG-PLACEBO-LIP, and PLACEBO-LIP were administered intravenously 20 h after inoculation.
c Each value represents the geometric mean 6 standard deviation.
d Effect of treatment was determined at 48 h (n 5 10) as well as 6 days (n 5 10) after treatment.
e P # 0.01 compared with the number of CFU at 20 h after inoculation (time of treatment).
f P # 0.01 compared with the number of CFU at 48 h after treatment.
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icant reduction in the numbers of C. albicans organisms in the
liver (P # 0.025), spleen (P # 0.001), and lung (P # 0.001)
(data not shown); however, in the kidney the growth of C.
albicans was only inhibited, and the numbers of C. albicans
organisms were not significantly reduced. Although an increase
in the dose of AmB-LIP up to the MTD (11 mg of AmB per
kg) resulted in a slight improvement in efficacy compared with
a dose of 5 mg of AmB per kg, it did not result in complete
efficacy of treatment, as seen with PEG-AmB-LIP at 5 mg of
AmB per kg; with 11 mg of AmB per kg the numbers of C.
albicans organisms in the kidney were significantly reduced
compared with the numbers at the time of treatment only at 6
days after treatment. AmBisome at a dose of 5 mg of AmB per
kg was not effective, because the animals died after treatment.
AmBisome at the MTD (29 mg of AmB per kg) was as effective
as PEG-AmB-LIP at 5 mg of AmB per kg.
DISCUSSION
With respect to the in vitro antifungal activity of the AmB
liposome formulations against C. albicans, it is derived from
the results of the present study that after encapsulation of
AmB in PEG-AmB-LIP or AmB-LIP the high degree of anti-
fungal activity seen with AmB-DOC is almost fully retained,
whereas entrapment of AmB in AmBisome is accompanied by
a substantial loss of antifungal activity. Although it was previ-
ously shown that AmB-DOC and AmBisome were equally
active after long-term exposure (MIC, minimum fungicidal
concentration) (7, 29), the activity of AmBisome during short-
term exposure was significantly less than that of AmB-DOC
(29). Recently, it was reported (24) that even after long-term
exposure (24 h) AmBisome was four to eight times less active
than AmB-DOC against C. albicans.
Comparison of the MTD of the industrially prepared Am-
Bisome in healthy mice (.31 mg of AmB per kg) and the MTD
of a laboratory-prepared AmB liposome formulation (AmB-
LIP) with the same lipid composition (19 mg of AmB per kg)
revealed that the method of preparation greatly influences the
toxicity of the AmB liposome formulation. Because the MTD
of AmB-DOC in terms of the number of acute deaths after a
single-dose treatment is 0.8 mg of AmB per kg (unpublished
data), encapsulation of AmB in AmB-LIP still substantially
reduced the toxicity of AmB. To the same extent, this also
applied to PEG-AmB-LIP (MTD, 15 mg of AmB/kg).
The prolonged residence time of PEG-AmB-LIP compared
with that of AmB-LIP was previously demonstrated at a dose
of 9 mg of AmB per kg (corresponding to 85 mmol of lipid per
kg) (30). A valuable asset of the PEG-PE-containing liposomes
is that they show dose-independent pharmacokinetics (4, 5, 25,
33). Taking together the data from our present study and our
previous study (30), we conclude that for PEG-AmB-LIP a
prolonged blood residence time does not depend on the lipid
dose for a dose range of 4.7 to 85 mmol of lipid per kg. These
results are in good agreement with those reported elsewhere
for PEG-PE liposomes with similar particle sizes (4, 5, 25, 33),
demonstrating dose-independent blood circulation times for
dose ranges of 0.5 to 500 mmol/kg in mice (4, 25, 33) and 3 to
100 mmol/kg (5, 33) in rats. On the contrary, as reported
previously by Allen and Hansen (4), the blood residence times
of small liposomes of approximately 100 nm in diameter with a
rigid liposomal bilayer and without surface modifications are
dependent on the lipid dose given. In the present study it was
shown that the blood residence time of AmB-LIP depends on
the lipid dose, which is in accordance with the previous obser-
vations (4). For AmBisome, the dose-dependent blood circu-
lation of AmB was already reported previously (13, 17, 26, 28).
The extent to which a prolonged residence time of liposomal
AmB is of importance for improved therapeutic efficacy was
studied in a model of systemic candidiasis in leukopenic mice
after a single-dose treatment. The efficacies of PEG-AmB-LIP,
AmB-LIP, and AmBisome were compared by using equivalent
doses of 5 mg of AmB per kg (which is the MTD of PEG-
AmB-LIP in leukopenic infected mice). At this dose treatment
with PEG-AmB-LIP was completely effective, but treatment
with AmB-LIP was only partially effective. We conclude that
therapeutic efficacy in this model of deep systemic candidiasis
is favored by the prolonged residence time of AmB liposomes
in the blood compartment. Whether this is due to the sustained
release of AmB during circulation in the blood or increased
localization of AmB liposomes at the sites of infection, as was
described by others for a localized site of infection (8) or a
solid tumor (19, 25), is not yet clear. AmBisome at 5 mg of
AmB per kg was not effective at all. Additionally, AmB-LIP
and AmBisome were both studied at their own MTDs. Com-
plete efficacy of treatment could not be achieved with AmB-
LIP, not even after an increase in the dose to 11 mg of AmB
per kg (the MTD). AmBisome at 29 mg of AmB per kg (the
MTD) was as effective as treatment with PEG-AmB-LIP at the
almost sixfold lower dose of 5 mg of AmB per kg. Until now,
the efficacy of AmBisome has been compared with that of
AmB-DOC in several models of fungal infections (1, 10, 11, 13,
17, 29). From those studies it can be concluded that, depending
on the model of fungal infection, the immune status of the
host, and the parameter of efficacy used, the antifungal activity
of AmBisome is either somewhat less than or equal to that of
AmB-DOC with equivalent doses of AmB. However, treat-
ment with AmB-DOC is restricted by acute toxicity. By using
AmBisome, much higher doses are tolerated, resulting in im-
proved antifungal efficacy, even against severe infections in
immunocompromised animals. Only recently (24), the inter-
pretation of the data from these experimental studies on Am-
Bisome has been critically discussed. The investigators rightly
note that a difference in toxicity, and thereby in the therapeutic
index, between AmBisome and AmB-DOC has always been
claimed on the basis of the acute toxicity of rapidly injected
AmB-DOC in small laboratory animals. As in patients, AmB-
DOC is not administered as an intravenous bolus but is ad-
ministered by slow infusion; the investigators studied the
therapeutic efficacies of both AmB-DOC and AmBisome in
localized and systemic murine candidiases, with AmB-DOC
administered at high doses in multiple fractions. The observa-
tion that AmBisome was less active than high doses of AmB-
DOC indicates that by entrapment of AmB in liposomes, ther-
apeutic efficacy might be reduced. From the present study it is
also clear that with AmBisome a reduction in toxicity is con-
comitant with a reduction in antifungal activity, and thereby in
antifungal efficacy in vivo. At an equivalent dose, AmB-LIP, a
formulation with which somewhat less reduction in toxicity
occurs together with retained antifungal activity, shows better
antifungal efficacy in vivo.
By combining the data on toxicity, antifungal activity, blood
residence time, and efficacy of treatment, two important con-
clusions can be drawn. First, from a comparison between lab-
oratory-prepared AmB-LIP with industrially prepared AmBi-
some, it is clear that the method of preparation of an AmB
liposome formulation greatly influences the toxicity and anti-
fungal activity, and thereby the antifungal efficacy, in vivo. It
should be stressed that a maximal reduction of AmB toxicity
results in a concomitant loss of antifungal activity and efficacy.
Therefore, for optimization of the preparation of AmB lipo-
somes it is important to focus on both a reduction in AmB
toxicity and retained antifungal activity. This is achieved in
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both AmB-LIP and PEG-AmB-LIP. The second conclusion
derived by comparing PEG-AmB-LIP and AmB-LIP is that
therapeutic efficacy is favored by a prolonged residence time of
AmB liposomes in the blood compartment.
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